非CTX-M型超广谱β-内酰胺酶肠杆菌目血流感染是否必须使用碳青霉烯类治疗?
多中心观察性研究纳入2018-2022年500例头孢曲松耐药肠杆菌目血流感染连续患者,经肉汤微量稀释和全基因组测序确认396例(79.2%)为ESBL-E血流感染。采用倾向评分逆概率加权后,非CTX-M组与CTX-M组的30天死亡率(OR 0.99,95%CI 0.87-1.11,P=0.83)和复发率(OR 1.10,95%CI 0.85-1.42,P=0.47)无差异。探索性分析中,非CTX-M组接受美罗培南的21例有86%第30天存活,接受哌拉西林-他唑巴坦的5例均未存活。
要点
- 非CTX-M与CTX-M型ESBL-E血流感染的30天死亡率和复发率无显著差异。
- 非CTX-M组接受美罗培南的21例中86%第30天存活,接受哌拉西林-他唑巴坦的5例均未存活。
- 作者认为美罗培南可能与改善非CTX-M型ESBL-E血流感染患者生存相关。
核心结论
- 作者认为非CTX-M与CTX-M型ESBL-E血流感染同样值得关注且临床结局相似。
- 美罗培南可能与改善非CTX-M型ESBL-E血流感染患者生存相关,作者强调全面分子诊断有助于早期优化抗生素治疗。
研究设计与样本
- 多中心观察性研究,纳入2018-2022年500例连续的头孢曲松耐药肠杆菌目血流感染患者。
- 采用肉汤微量稀释法确认抗生素敏感性,全基因组测序确认ESBL基因存在。
- 采用基于倾向评分的逆概率加权(IPW)使非CTX-M组与CTX-M组在结局评估前具有可比性。
主要发现
- 396例(79.2%)确诊为ESBL-E血流感染,ESBL基因家族分布为blaCTX-M(n=370)、blaSHV(n=16)、blaOXY(n=12)、blaVEB(n=5)。
- ESBL基因鉴定不限于大肠埃希菌和克雷伯菌属。
- 在IPW队列中,非CTX-M组与CTX-M组的30天死亡率无差异(OR 0.99,95%CI 0.87-1.11,P=0.83)。
- 在IPW队列中,非CTX-M组与CTX-M组的ESBL-E感染复发无差异(OR 1.10,95%CI 0.85-1.42,P=0.47)。
- 在仅限非CTX-M组的探索性分析中,接受美罗培南的21例患者有86%第30天存活,接受哌拉西林-他唑巴坦的5例患者均未存活。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Investigations into antibiotics for extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) bloodstream infections (BSIs) have focused on blaCTX-M genes. Patient outcomes from non-CTX-M-producing ESBL-E BSIs and optimal treatment are unknown. METHODS: A multicenter observational study investigating 500 consecutive patients with ceftriaxone-resistant Enterobacterales BSIs during 2018-2022 was conducted. Broth microdilution and whole-genome sequencing confirmed antibiotic susceptibilities and ESBL gene presence, respectively. Inverse probability weighting (IPW) using propensity scores ensured patients with non-CTX-M and CTX-M ESBL-E BSIs were similar before outcome evaluation. RESULTS: 396 patients (79.2%) were confirmed to have an ESBL-E BSI. ESBL gene family prevalence was as follows: blaCTX-M (n = 370), blaSHV (n = 16), blaOXY (n = 12), and blaVEB (n = 5). ESBL gene identification was not limited to Escherichia coli and Klebsiella species. In the IPW cohort, there was no difference in 30-day mortality or ESBL-E infection recurrence between the non-CTX-M and CTX-M groups (odds ratio [OR], 0.99; 95% confidence interval [CI], .87-1.11; P = .83 and OR, 1.10; 95% CI, .85-1.42; P = .47, respectively). In an exploratory analysis limited to the non-CTX-M group, 86% of the 21 patients who received meropenem were alive on day 30; none of the 5 patients who received piperacillin-tazobactam were alive on day 30. CONCLUSIONS: Our findings suggest that non-CTX-M and CTX-M ESBL-E BSIs are equally concerning and associated with similar clinical outcomes. Meropenem may be associated with improved survival in patients with non-CTX-M ESBL-E BSIs, underscoring the potential benefit of comprehensive molecular diagnostics to enable early antibiotic optimization for ESBL-E BSIs beyond just blaCTX-M genes.
引用
- Hareza DA, Cosgrove SE, Simner PJ, et al. Is Carbapenem Therapy Necessary for the Treatment of Non-CTX-M Extended-Spectrum β-Lactamase-Producing Enterobacterales Bloodstream Infections? Clin Infect Dis. 2024. PMID: 37972276. doi:10.1093/cid/ciad703
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。